Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Adherium Limited (ADR.AX)
AUD0.11
-0.02 (-15.38%)
NZ ASX Healthcare Medical - Devices
Address
63 Albert Street 1010
Melbourne, NZ
Melbourne, NZ
CEO
Dawn Bitz
Website
adherium.com
IPO
2015-08-26
ISIN AU000000ADR1
Description
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanning New Zealand, Australia, Europe, North America, and Asia. A central offering is Hailie, a comprehensive system engineered to optimize medication use for patients suffering from chronic respiratory illnesses like asthma and chronic obstructive pulmonary disease (COPD). This innovative solution integrates Bluetooth-enabled Hailie sensors, which discreetly attach to patients' inhalers to deliver immediate feedback. The Hailie ecosystem is further supported by an intuitive mobile application and a dedicated online portal. Established in 2001, Adherium Limited is headquartered in Auckland, New Zealand.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.11
-0.02 (-15.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5.8K
Beta
1.01
Float Shares
1.72B
Free Float %
89.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -50.00% | -60.00% | -71.42% | -96.19% | -99.17% | -99.97% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.11
Ratings Trend (MoM)
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-69.61
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-2.8% Q4'25: +112.5% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+48.7% ★ Q4'25: +81.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-1,254.4% Q4'25: -930.5% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-1,534.3% Q4'25: -745.6% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%— Q4'25: +22,648.4% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+142.4% Q4'25: +588.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.25× Q4'25: -0.06× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.10M
est: 3.23M (-34.9%)
|
2.35M
est: 3.81M (-38.4%)
|
5.87M
est: 8.28M (-29.1%)
|
2.78M
est: 3.05M (-8.9%)
|
2.22M
est: 3.98M (-44.2%)
|
401.0K
est: 3.96M (-89.9%)
|
529.0K
est: 798.3K (-33.7%)
|
3.20M
est: 2.98M (+7.3%)
|
841.0K
est: 9.77M (-91.4%)
|
817.2K
est: 4.30M (-81.0%)
|
18.48M
18.48M – 18.48M
+329.5% YoY
|
45.26M
45.26M – 45.26M
+144.9% YoY
|
| EBITDA |
-6.56M
est: -3.23M (-103.5%)
|
-13.83M
est: -3.81M (-262.9%)
|
-10.14M
est: -23.23M (+56.3%)
|
-11.38M
est: -3.05M (-272.9%)
|
-8.46M
est: -3.98M (-112.8%)
|
-13.03M
est: -3.96M (-229.2%)
|
-12.66M
est: -798.3K (-1,485.2%)
|
-11.50M
est: -2.98M (-286.3%)
|
-11.56M
est: -9.77M (-18.3%)
|
-12.44M
est: -4.30M (-189.1%)
|
-18.48M
-18.48M – -18.48M
-329.5% YoY
|
-45.26M
-45.26M – -45.26M
-144.9% YoY
|
| EBIT |
-6.00M
est: -3.23M (-86.2%)
|
-14.10M
est: -3.81M (-270.0%)
|
-9.34M
est: -23.23M (+59.8%)
|
-11.79M
est: -3.05M (-286.3%)
|
-8.80M
est: -3.98M (-121.3%)
|
-13.17M
est: -3.96M (-232.8%)
|
-12.85M
est: -798.3K (-1,509.7%)
|
-11.69M
est: -2.98M (-292.7%)
|
-11.67M
est: -9.77M (-19.4%)
|
-12.54M
est: -4.30M (-191.5%)
|
-18.48M
-18.48M – -18.48M
-329.5% YoY
|
-45.26M
-45.26M – -45.26M
-144.9% YoY
|
| Net Income |
-6.31M
est: -434.13M (+98.5%)
|
-12.81M
est: -609.21M (+97.9%)
|
-9.34M
est: -23.23M (+59.8%)
|
-11.79M
est: -190.98M (+93.8%)
|
-11.40M
est: -98.77M (+88.5%)
|
-15.04M
est: -98.32M (+84.7%)
|
-10.04M
est: -5.52B (+99.8%)
|
-9.86M
est: -5.66B (+99.8%)
|
-10.22M
est: -259.01M (+96.1%)
|
-12.68M
est: -907.47M (+98.6%)
|
-382.84M
-382.84M – -382.84M
+57.8% YoY
|
737.92M
737.92M – 737.92M
+292.7% YoY
|
| SGA |
5.55M
est: 32.56M (-83.0%)
|
9.57M
est: 38.48M (-75.1%)
|
9.10M
est: 83.60M (-89.1%)
|
7.37M
est: 30.81M (-76.1%)
|
5.54M
est: 40.13M (-86.2%)
|
6.10M
est: 39.95M (-84.7%)
|
6.27M
est: 8.06M (-22.2%)
|
8.88M
est: 30.05M (-70.5%)
|
7.20M
est: 98.66M (-92.7%)
|
9.86M
est: 43.43M (-77.3%)
|
186.54M
186.54M – 186.54M
+329.5% YoY
|
456.89M
456.89M – 456.89M
+144.9% YoY
|
| EPS |
-0.76
est: -0.48 (-57.5%)
|
-0.08
est: -0.68 (+88.8%)
|
-0.81
est: -0.57 (-42.8%)
|
-1.02
est: -0.21 (-380.6%)
|
-0.54
est: -0.11 (-391.9%)
|
-0.25
est: -0.11 (-128.8%)
|
-0.07
est: -6.14 (+98.9%)
|
-0.04
est: -6.30 (+99.4%)
|
-0.03
est: -0.29 (+90.4%)
|
-0.01
est: -1.01 (+98.6%)
|
-0.43
-0.43 – -0.43
+57.8% YoY
|
0.82
0.82 – 0.82
+292.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-22.43M
OE per share TTM
-0.03
Owner's Yield
-475.25%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
13.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-3.1K
Shares Outstanding
1.93B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Motion | Consultant | 1M | male |
| Dawn Bitz | Chief Executive Officer | 622.2K | female |
| Emily Austin | Company Secretary | 132.0K | female |
| John Douglas Wilson | Executive Medical Director | 11.1K | — |
| Julie Quinlan | Head of People and Culture | — | female |
| Catherine Morgan | Head of Regulatory & Quality | — | female |
| Tom Quinlan | Caretaker Chief Financial Officer | — | male |
| David Haddad | Head of Product | — | male |
| Hetal Dhruve | Head of Medical & Clinical Affairs | — | female |
| Jason Hochman | Head of US Commercial/GTM | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADR.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
